Immunotherapy and chemotherapy for lung cancer with HIV and long covid
Part of Cancer, Infections, Lungs & breathing clinical trials.
This trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus chemotherapy for people with advanced lung cancer who also have HIV and Long Covid syndrome. The goal is to see if this treatment is safe and effective for this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced non-small cell lung cancer (NSCLC) that has spread or cannot be removed with surgery.
- You must not have certain genetic changes in your tumor (like EGFR, ALK, ROS1, BRAF, or NTRK).
- You should be able to do light housework or office work (ECOG score 0 or 1).
- You must not have had any prior cancer treatment (like chemotherapy or immunotherapy).
- You need to have an HIV infection (HIV-1 or HIV-2) and have Long Covid syndrome.
- You must not have active hepatitis B or C, and you cannot have an active COVID-19 infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy as a first treatment for advanced lung cancer that has spread or come back. It may help if your cancer hasn't been treated before and doesn't have certain genetic changes.
This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This trial tests a combination of immune therapy drugs (durvalumab and tremelimumab) given with chemotherapy in people with stage IV non-small cell lung cancer who also have HIV. It may help shrink or control cancer by boosting the immune response while keeping HIV well controlled.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.